Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Oct 1;108(10):2799-2802.
doi: 10.3324/haematol.2022.282510.

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients

Nico Gagelmann  1 , Francis A Ayuk  1 , Evgeny Klyuchnikov  1 , Christine Wolschke  1 , Susanna Carolina Berger  1 , Nicolaus Kröger  2
Affiliations
Meta-Analysis

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients

Nico Gagelmann et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Results of the meta-analysis of outcomes of patients with or without extramedullar disease. (A) Overall response rate. (B) Progression-free survival. EMD: extramedullary discase; RR: risk ratio; CI: confidence interval.
Figure 2.
Figure 2.
Results of the meta-analysis of outcomes for patients with high-risk versus standard-risk cytogenetics. (A) Overall response rate. (B) Progression-free survival. RR: risk ratio; CI: confidence interval.
See this image and copyright information in PMC

Comment in

References

    1. Bruno B, Wäsch R, Engelhardt M, et al. . European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. 2021;106(8):2054-2065. - PMC - PubMed
    1. Gagelmann N, Riecken K, Wolschke C, et al. . Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317-2332. - PubMed
    1. Munshi NC, Anderson LD, Shah N, et al. . Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716. - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. - PubMed
    1. Gagelmann N, Ayuk F, Atanackovic D, Kröger N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2020;104(4):318-327. - PubMed

Publication types

MeSH terms

Substances